Table 1.
Subjects’ characteristics
| Patients | Healthy controls | p | ||
|---|---|---|---|---|
| Age (years; mean ± SD) | 62.3 ± 11.2 | 63.5 ± 11.7 | .85a | |
| Gender (male/female) | 9/4 | 9/4 | 1 | |
| Diagnosis (blepharospasm/Meige′s) | 9/4 | — | — | |
| Disease duration (years; mean ± SD) | 9.3 ± 7.0 | — | — | |
| Interval BTX—post‐BTX MRI (days; mean ± SD) | 30.1 ± 3.8 | — | — | |
| Interval BTX—pre‐BTX MRI (days; mean ± SD) | 87.8 ± 12.5 | — | — | |
| BTX treatment | ||||
| Abobotulinum toxin (n; mean of dose ± SD) | 6; 165 ± 34.3 | — | — | |
| Onabotulinum toxin (n; mean of dose ± SD) | 5; 33.75 ± 8.51 | — | — | |
| Incobotulinum toxin (n; mean of dose ± SD) | 2; 63.75 ± 11.25 | — | — | |
| Pre‐BTX | Post‐BTX | |||
| Blepharospasm disability scale (mean ± SD) | 0.54 ± 0.24 | 0.63 ± 0.28 | — | .109b |
| Jankovic rating scale (mean ± SD) | 4.1 ± 2.6 | 3.4 ± 2.2 | — | .413b |
| Number of blinks during rsfMRI (642.6 s) detected by electromyography (mean ± SD) | 277.4 ± 292.7 | 276.0 ± 346.3 | 233.3 ± 181.4 | .66c.70d.97e |
Blepharospasm/OFD patients and healthy controls were matched in respect of gender and age (±5 years).
BTX, botulinum toxin; pre‐/post‐BTX, before/after BTX treatment; rsfMRI, resting‐state functional magnetic resonance imaging; SD, standard deviation.
a
Independent‐sample t test.
b
Wilcoxon signed‐rank test.
c
pre‐BTX versus HC; independent‐sample t test.
d
post‐BTX versus HC; independent‐sample t test.
e
pre‐BTX versus post‐BTX; paired t test.